ASCO 2022 Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment for HER2+ Gastric and GEJ Adenocarcinoma

129 views
June 17, 2022
0 Comments
Login to view comments. Click here to Login